GERO, a leading AI-driven biotechnology company focused on aging
and longevity and FOXO Technologies Inc. (NYSEAM: FOXO), a leader
in epigenetic biomarker discovery and commercialization, today
announced the commencement of discussions to form a strategic
collaboration between the two companies. As a result, FOXO and GERO
will seek to develop an AI-driven personalized wellness and
longevity recommendation engine based on proprietary epigenetic
data.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230807313578/en/
This collaboration occurs in the wake of recent advancements
from GERO, which sparked vigorous discussion among longevity
experts in the scientific community when a story was published in
Popular Mechanics that asserted Humans Can Stop—But Not Fully
Reverse—Aging. GERO’s machine-learning technology platform is being
applied to discover potential therapeutic targets for fibrotic
diseases using large-scale human data in collaboration with a large
biopharma.
What this means for wellness and longevity
FOXO Technology’s unique datasets are a missing link in
understanding the utility, reliability, and reversibility of
epigenetic signatures of health and longevity. Augmented by GERO´s
AI-driven understanding of human aging, this collaboration promises
to enhance risk segmentation of individuals based on longitudinal
changes in their epigenetic patterns. The overarching goal of this
joint effort is to uncover new ways to personalize lifestyle-based
interventions to delay the onset of chronic diseases and,
ultimately, mortality.
What this means for longevity biotechnology
GERO and FOXO share the goal of helping people live healthier
for longer, whether through the development of new diagnostics and
therapeutics, or by lifestyle modifications. FOXO’s founding was
based, in part, on the discovery of “epigenetic clocks” — a
benchmark measure of biological aging, in which FOXO’s Chief
Science Officer Dr. Brian Chen played a key role in demonstrating
its utility. Since its founding, FOXO has generated data and
partnerships to accelerate the development and commercialization of
epigenetic signatures with the goal of gaining unique insights to
one’s health and longevity.
Dr. Peter Fedichev [CEO and co-founder of GERO], sees enormous
promise for the insights derived from longitudinal epigenetic data
to address life and health span.
“Our goal is to slow down or even stop human aging. Epigenetics
has revolutionized the way in which the field has thought about
biological aging, but we have only scratched the surface. With
FOXO’s unique expertise and resources, we hope to unlock more
nuanced relationships between epigenetics and aging that haven’t
been previously understood,” commented Fedichev.
GERO invites partnerships for novel target identification and
comprehensive drug discovery collaborations, as exemplified by its
recent work with a biopharma leader. GERO’s scientific excellence
and outstanding drug-discovery capabilities are the basis for the
range of landmark papers in aging and drug discovery fields that
shape the future of the industry, published in numerous magazines,
including Nature Communications (1, 2, 3), and Science journals and
are covered by Scientific American, Popular Mechanics (5, 6), and
other media outlets.
About GERO
GERO is a biotechnology company using physics-based generative
models on human health record datasets, combined with AI-guided
drug design, to develop transformative interventions for aging and
age-related diseases. To achieve this goal, GERO acquired a massive
dataset of longitudinal, real-world medical records and built a
generative, very large model of human health. The model is based on
principles adopted from the physics of complex and dynamic systems
and reveals the irreversible nature of human aging while
highlighting the reversible aspects of diseases, distinguishing the
two phenomena. It also reveals causal relationships between
microscopic molecular- and organism-level features associated with
diseases to enable rapid targeting and drug discovery, directly in
human data.
GERO’s preclinical stage drug candidate demonstrates promising
potential in addressing a diverse spectrum of neurodegenerative
diseases. A separate ongoing drug discovery project to develop an
anti-aging vaccine, instrumental in the treatment of
senescence-associated diseases, has resulted in one of the most
robust mice rejuvenation results globally. GERO’s other earlier
stage highly ambitious project aims to identify a drug aimed at
significantly decelerating the aging process. The company’s
published research (7, 8), supports the notion that targeting the
specific phenotype — the rate at which humans lose resilience —
holds the key to achieving a substantial, several-fold extension of
health span and life span, far exceeding so-called natural
limits.
To learn more about how GERO is hacking complex diseases and
aging, visit gero.ai and check out the latest interviews of GERO
CEO Peter Fedichev: video and text.
About FOXO Technologies Inc. (“FOXO”)
FOXO Technologies is a pioneering biotechnology company at the
forefront of commercializing epigenetic biomarker technology. Their
mission is to utilize the power of epigenetics and artificial
intelligence to generate data-driven insights that promote optimal
health and longevity outcomes for individuals and organizations
alike. For more information about FOXO, visit
www.foxotechnologies.com.
Forward-Looking Statements
This press release contains certain forward-looking statements
for purposes of the “safe harbor” provisions under the United
States Private Securities Litigation Reform Act of 1995. Any
statements other than statements of historical fact contained
herein, including statements as to future results of operations and
financial position, planned products and services, business
strategy and plans, objectives of management for future operations
of FOXO, market size and growth opportunities, competitive position
and technological and market trends, are forward-looking
statements. Such forward-looking statements include, but not
limited to, expectations, hopes, beliefs, intentions, plans,
prospects, financial results or strategies regarding FOXO, whether
FOXO and GERO will form a strategic collaboration; whether any
strategic collaboration between FOXO and GERO will enable FOXO and
GERO to develop an AI-driven personalized wellness and longevity
recommendation engine, enhance risk segmentation of individuals
based on longitudinal changes in their epigenetic patterns, or
uncover new ways to personalize lifestyle-based interventions that
can delay the onset of chronic diseases and mortality; the future
financial condition and performance of FOXO and the products and
markets and expected future performance and market opportunities of
FOXO. These forward-looking statements generally are identified by
the words “anticipate,” “believe,” “could,” “expect,” “estimate,”
“future,” “intend,” “strategy,” “may,” “might,” “strategy,”
“opportunity,” “plan,” project,” “possible,” “potential,”
“project,” “predict,” “scales,” “representative of,” “valuation,”
“should,” “will,” “would,” “will be,” “will continue,” “will likely
result,” and similar expressions, but the absence of these words
does not mean that a statement is not forward-looking.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to: (i) the risk of changes in
the competitive and highly regulated industries in which FOXO
operates, variations in operating performance across competitors or
changes in laws and regulations affecting FOXO’s business; (ii) the
ability to implement FOXO’s business plans, forecasts, and other
expectations; (iii) the ability to obtain financing if needed; (iv)
the ability to maintain its NYSE American listing; (v) the risk
that FOXO has a history of losses and may not achieve or maintain
profitability in the future; (vi) potential inability of FOXO to
establish or maintain relationships required to advance its goals
or to achieve its commercialization and development plans; (vii)
the enforceability of FOXO’s intellectual property, including its
patents and the potential infringement on the intellectual property
rights of others; and (viii) the risk of downturns and a changing
regulatory landscape in the highly competitive biotechnology
industry or in the markets or industries in which FOXO’s
prospective customers operate. The foregoing list of factors is not
exhaustive. Readers should carefully consider the foregoing factors
and the other risks and uncertainties discussed in FOXO’s most
recent reports on Forms 10-K and 10-Q, particularly the “Risk
Factors” sections of those reports, and in other documents FOXO has
filed, or will file, with the SEC. These filings identify and
address other important risks and uncertainties that could cause
actual events and results to differ materially from those contained
in the forward-looking statements. Forward-looking statements speak
only as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and FOXO assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230807313578/en/
FOXO Contacts / Investor Relations
Matthew Hausch, Cody Slach Gateway Investor Relations (949)
574-3860 FOXO@gatewayir.com
GERO Contacts / Investor Relations Alexey Strygin Chief
Digital Health Officer Alexey.strygin@gero.ai
FOXO Technologies (AMEX:FOXO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
FOXO Technologies (AMEX:FOXO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024